metricas
covid
Clinics Most cited
Journal Information

Most cited

Data available in articles published since the year 2017

42
Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy
Bojana Gutic, Tatjana Bozanovic, Aljosa Mandic, Stefan Dugalic, Jovana Todorovic, Dejana Stanisavljevic, Miroslava Gojnic Dugalic, Demet Sengul, ... José Maria Soares
Clinics. 2023;78C:100177
42
Highlights

  • Recently, cancer immunotherapy targeting PD-1 or PD-L1 has proven effective in causing durable antitumor immune responses with less toxicity in many types of tumors.

  • PD-1/PD-L1 blockade therapy will be the major cancer immunotherapy modality.

  • A deeper understanding of personal genomic information, and personalized markers in guiding anti-PD therapy.

  • Similar to the tip of an iceberg, PD-1/PD-L1 blockade antitumor immunotherapy opens a new era of cancer treatment, and further work on safety and efficiency will be required.

Full text access
39
The weight-adjusted-waist index predicts all-cause and cardiovascular mortality in general US adults
Ying Han, Jieli Shi, Pengfei Gao, Lin Zhang, Xuejiao Niu, Na Fu
Clinics. 2023;78C:100248
39
Highlights

  • WWI was a potential predictor for cardiovascular mortality with a cut-off of 11.33.

  • Higher WWI associated with an increased 95% risk for cardiovascular mortality.

  • Higher WWI associated with an increased 68% risk for all-cause mortality.

Full text access
35
Pesticide exposure and human health: Toxic legacy
Fulvio A. Scorza, Larissa Beltramim, Larissa M. Bombardi
Clinics. 2023;78C:100249
35
Full text access
20
Prevalence of chronic pain in Brazil: A systematic review and meta-analysis
Bruno Vitor Martins Santiago, Ana Beatriz Garcez de Oliveira, Gabriel Machado Romão da Silva, Maxuel de Freitas da Silva, Pedro Ernandes Bergamo, Maud Parise, Nivaldo Ribeiro Villela
Clinics. 2023;78C:100209
20
Highlights

  • The prevalence of chronic pain in the adult population (35.70%) and older adults (47.32%).

  • Differs from region to region and is associated with heterogeneous risk factors.

  • Manifested mainly with moderate or severe intensity and with an elevated rate of disability.

Full text access
19
Does bisphenol A (BPA) participates in the pathogenesis of Polycystic Ovary Syndrome (PCOS)?
Lorena Ana Mercedes Lara Urbanetz, José Maria Soares Junior, Gustavo Arantes Rosa Maciel, Ricardo dos Santos Simões, Maria Cândida Pinheiro Baracat, Edmund Chada Baracat
Clinics. 2023;78C:100310
19
Highlights

  • Bisphenola A (BPA) is an endocrine disruptor widely investigated as a possible environmental contributor to the pathogenesis of Polycystic Ovary Syndrome (PCOS).

  • Due to its structural similarity with the Estrogen molecule (E2), it acts as a xenoestrogen, binding to genomic and non-genomic estrogen receptors, causing metabolic and hormonal changes that lead to PCOS (hyperandrogenism, insulin resistance, hyperinsulinemia, obesity, atherogenic dyslipidemia, anovulation, and ovarian cysts).

  • The aim and of this review were to present the mechanisms of bisphenol A participation in the pathogenesis of Polycystic Ovary Syndrome.

Full text access
16
Butyrate facilitates immune clearance of colorectal cancer cells by suppressing STAT1-mediated PD-L1 expression
Yan Zhang, Yuan Tao, Yuqing Gu, Qiujie Ma
Clinics. 2023;78C:100303
16
Highlights

  • Butyrate could suppress IFN-γ-induced PD-L1 up-regulation in Colorectal Cancer (CRC) cells.

  • Butyrate promoted the lysine acetylation of STAT1 to reduce STAT1 expression.

  • Butyrate attenuated the IFN-γ-induced impairment of CD8+ T-cell cytotoxicity against CRC cells.

  • Butyrate suppressed CRC tumor growth by enhancing CD8+ T-cell infiltration.

Full text access
14
Immunotherapy in the treatment of chemoresistant gestational trophoblastic neoplasia - systematic review with a presentation of the first 4 Brazilian cases
Antonio Braga, Elaine Balthar, Laís Cristhine Santos Souza, Michelle Samora, Matheus Rech, José Mauro Madi, Joffre Amim Junior, Jorge Rezende Filho, ... Ross S. Berkowitz
Clinics. 2023;78C:100260
14
Highlights

  • Gestational trophoblastic neoplasia responds to anti-PD-1 or anti-PD-L1 immunotherapy.

  • Multi-drug resistant gestational trophoblastic neoplasia may achieve remission with pembrolizumab.

Full text access
13
Deep learning for diagnosis of malign pleural effusion on computed tomography images
Neslihan Ozcelik, Ali Erdem Ozcelik, Nese Merve Guner Zirih, Inci Selimoglu, Aziz Gumus
Clinics. 2023;78C:100210
13
Highlights

  • Decision support systems that can predict the diagnosis of malignancy for pleural effusion will help physicians in patient management.

  • Advances in computer-aided diagnostic analysis of CT images and obtaining a pre-diagnosis of pleural fluid may reduce the need for interventional procedures by guiding physicians about which patients may have malignancy.

  • Image-based decision support systems enable early diagnosis and treatment by saving cost and time in patient management.

Full text access
13
Transforming the invisible into the visible: disparities in the access to health in LGBT+ older people
Milton Roberto Furst Crenitte, Leonardo Rabelo de Melo, Wilson Jacob-Filho, Thiago Junqueira Avelino-Silva
Clinics. 2023;78C:100149
13
Highlights

  • LGBT+ people can face several inequalities in access to healthcare.

  • LGBT+ people performed fewer preventive exams than their non-LGBT+ peers.

  • The worst access score was found in black LGBT+ over 50 years old.

Full text access
13
Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre
Bojana Gutic, Tatjana Bozanovic, Aljosa Mandic, Stefan Dugalic, Jovana Todorovic, Miroslava Gojnic Dugalic, Demet Sengul, Dzenana A. Detanac, ... José Maria Soares Junior
Clinics. 2023;78C:100204
13
Highlights

  • Analyzing predictors of survival in patients with ovarian carcinoma is crucial.

  • Independent estimators of mortality in ovarian carcinoma, are more precise by identifying histopathologic tumor grade, FIGO, and NACT.

  • The aforementioned predictors also involve the number of therapeutic cycles, type of surgery, and chemotherapy response.

  • Poor chemotherapy response increases the hazard ratio for mortality.

  • Significant predictors of survival in ovarian carcinoma are the absence of recurrent disease and lymphovascular space invasion.

Full text access